Efficacy of Hylenex in the Treatment of Pain Among Hospice Patients

Completed · Not applicable · Has a placebo group

Conditions studied: Pain Management

In brief

The overall aim of this study is to find out whether Hylenex recombinant (for short, Hylenex) in subcutaneous (SC) injection improves the speed and effectiveness of SC opioids in hospice patients. Specifically, this study proposes to compare the level of self-reported pain in hospice patients started on SC infusions of morphine and hydromorphone (Dilaudid) over the initial 8 hours of opioid infusion with and without the preceded co-injection of Hylenex. Hospice patients include both home-bound patients as well as those under intensive care in hospice houses.

Key facts

Study ID
NCT00547664
Run by
HPC Healthcare, Inc.
People needed
88
Starts
2008-01-01
Expected to finish
2010-10-01
Last updated by the study team
2014-02-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.